학술논문
No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)
Document Type
Article
Author
Source
In: Therapeutic Advances in Neurological Disorders . (Therapeutic Advances in Neurological Disorders, 2021, 14)
Subject
Language
English
ISSN
17562864
17562856
17562856